Lanzhou Institute of Biological Products was established in August, 1934. Its predecessor was the Northwest Epidemic Prevention Department of the Central Committee of the Republic of China, and now it is under the central enterprise of the State Council State-owned Assets Supervision and Administration Commission: China Biotechnology Group. It is a large-scale high-tech state-owned pharmaceutical production enterprise integrating science, industry and trade, and also an important research institution of national medical microbiology, immunology, cytology and experimental animal science.
The research institute covers an area of 430,000 square meters with fixed assets of 246 million yuan. Existing staff 1700 people, including more than 380 senior technicians and 54 managers. There are many first-class projects and workshops that meet GMP standards. Among them, there are 5 research laboratories, including 14 departments involved in product production and 1 quality assurance department.
Lanzhou Institute of Biological Products develops and produces more than six kinds of products 100, such as vaccines, antitoxins, toxoids, blood products and diagnostic products, which are used to prevent, treat and diagnose various infectious diseases. Products are sold all over the country, and many scientific research achievements and products have won national awards, among which the adsorption and purification of pertussis vaccine and the new method of antigen-antibody detection won the second prize of national scientific and technological progress; The research on inactivated epidemic hemorrhagic fever vaccine won the first prize of national scientific and technological progress; The research and clinical application of botulinum toxin A won the second prize of national scientific and technological progress; The development of bivalent live vaccine for oral dysentery and oral rotavirus vaccine won the second prize of National Science and Technology Progress Award and DuPont Science and Technology Innovation Award. Oral dysentery vaccine is the only genetically engineered oral dysentery live vaccine in the world, which belongs to the national first-class new drug. Botulinum toxin type A was registered by KFDA, and became the first biological product exported by China. Oral rotavirus vaccine is the only product in the world that has been recognized at the national level. Anthrax vaccine, plague vaccine, botulinum toxin complete set products, etc. Exclusive production in China.
In order to standardize and internationalize the research and production of biological products, we have successively built modern production buildings for hepatitis B vaccine, blood preparation, rabies vaccine, anthrax vaccine and clean animals, as well as quality assurance, sub-packaging products and comprehensive management buildings. The production line of vaccine project invested by the state is more than 400 million RMB, which is relatively advanced internationally.